Holen Sie sich die Stockscreener-App
25.43
1.56%
0.39
Handel nachbörslich:
25.08
-0.35
-1.38%
Schlusskurs vom Vortag:
$25.04
Offen:
$25.15
24-Stunden-Volumen:
756.48K
Relative Volume:
1.17
Marktkapitalisierung:
$1.80B
Einnahmen:
$80.89M
Nettoeinkommen (Verlust:
$-144.73M
KGV:
-8.5623
EPS:
-2.97
Netto-Cashflow:
$-83.87M
1W Leistung:
+0.91%
1M Leistung:
+14.55%
6M Leistung:
+98.98%
1J Leistung:
+293.65%
1-Tages-Spanne:
$23.89
$25.46
1-Wochen-Bereich:
$23.51
$25.46
52-Wochen-Spanne:
$4.96
$27.60
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India
UBS sees upside for Nurix stock driven by promising NX-5948 data in CLL/SLL - Investing.com India
UBS Group Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
What is HC Wainwright’s Forecast for NRIX FY2024 Earnings? - Defense World
(NRIX) On The My Stocks Page - Stock Traders Daily
HC Wainwright Has Bullish Estimate for NRIX FY2024 Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - The Manila Times
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial - Clinical Trials Arena
WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Results from the - GlobeNewswire
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia - Yahoo Finance
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics stock soars to 52-week high of $26.31 By Investing.com - Investing.com South Africa
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.31 - Investing.com
The Manufacturers Life Insurance Company Purchases 4,583 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics adds pharma veteran Anil Kapur to board - Investing.com
Nurix Therapeutics adds pharma veteran Anil Kapur to board By Investing.com - Investing.com South Africa
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewswire
Take off with Nurix Therapeutics Inc (NRIX): Get ready for trading - SETE News
SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - Defense World
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nurix Therapeutics Inc-Aktie (NRIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Nov 04 '24 |
Sale |
25.00 |
3,290 |
82,250 |
28,084 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):